CST, 53373T, LIGHT/TNFSF14 (E1Y2S) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying TNFSF14. Validated for Western Blotting,Immunoprecipitation. Available in 2 sizes. Highly specific and rigorously validated in-house, LIGHT/TNFSF14 (E1Y2S) Rabbit Monoclonal Antibody (CST #53373) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:100 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity LIGHT/TNFSF14 (E1Y2S) Rabbit Monoclonal Antibody recognizes endogenous levels of total LIGHT/TNFSF14 protein. Species Reactivity: Human, Mouse Source / Purification Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the extracellular domain of human LIGHT/TNFSF14 protein. Background Tumor necrosis factor superfamily member 14 (TNFSF14), also known as CD258 and LIGHT, is a cell surface type II transmembrane protein that is expressed as a homotrimer (1). The extracellular region can be cleaved to generate a soluble cytokine (2). TNFSF14 is a ligand for the receptors herpesvirus entry mediator (HVEM) and lymphotoxin receptor (LTR) (1). TNFSF14 is expressed on activated NK cells, activated T cells, activated monocytes, immature DCs, and mast cells (1,3,4). TNFSF14 interactions with HVEM induce potent co-stimulatory signaling in T cells and trigger NK cells to produce IFN-γ via NF-κB RelA/p50 pathway signaling (5,6). TNFRSF14 produced by tumor-sensing NK cells aids in DC maturation, enabling anti-tumor adaptive immune responses (7). TNFSF14-HVEM interactions are considered the main drivers of anti-tumor immune responses, whereas TNFSF14-LTR interactions have been characterized as maintaining the infrastructure that supports the anti-tumor response via lymphoid development and cancer cells' susceptibility to the immune response (8,9). TNFSF14 induces the normalization of tumor vasculature, sensitizes tumor cells to IFN-γ-mediated apoptosis, and results in a more inflamed tumor microenvironment (TME) (6,8,10,11). Due to its effects on the TME and anti-tumor immune cell responses, TNFSF14 is being investigated as a target for immunotherapeutic intervention in cancer (9). TNFSF14 has also been implicated in the development and pathogenesis of inflammatory bowel disease and airway remodeling leading to asthma (12,13). Alternate Names CD258; Herpes virus entry mediator ligand; Herpesvirus entry mediator ligand; HVEM-L; HVEML; LIGHT; LTg; TNF superfamily member 14; TNF14; TNFSF14; TR2; tumor necrosis factor (ligand) superfamily, member 14; tumor necrosis factor ligand 1D; Tumor necrosis factor ligand superfamily member 14; Tumor necrosis factor ligand superfamily member 14, membrane form; Tumor necrosis factor ligand superfamily member 14, soluble form; tumor necrosis factor superfamily member 14 Specification REACTIVITY: H M SENSITIVITY: Endogenous MW (kDa): 28 Source/Isotype: Rabbit IgG